Impella Improves Survival from Cardiogenic Shock, but at a Price
Cardiogenic shock is a condition in which the heart is unable to pump with enough force to sustain life. Impella CP is a small pump implanted in the heart’s left ventricle to increase blood flow. In an international, multicenter study of patients in cardiogenic shock following a heart attack, published May 2024 in the New England Journal of Medicine, Impella saved more lives than standard treatment, but with a much higher rate of complications.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Heart Advisor
Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
